This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hims & Hers Scales AI-Driven Personalized Health and Wellness
by Debanjana Dey
HIMS scales AI-driven care with new hormonal health lines, global expansion plans and a $870 million funding boost.
Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings?
by Debanjana Dey
Hims & Hers benefits from strong platform engagement and hormonal health launches ahead of third-quarter 2025 earnings.
Analysts Estimate Nyxoah SA (NYXH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nyxoah (NYXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) reached $47.12 at the closing of the latest trading day, reflecting a -2.3% change compared to its last close.
HIMS vs. LFMD: Which Telehealth Stock Is the Better Investment Now?
by Zacks Equity Research
Hims & Hers and LifeMD are reshaping virtual care, but which one leads in earnings growth and platform scale? Let's dive in.
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
by Zacks Equity Research
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $47.46, marking a -3.85% move from the previous day.
Hims & Hers Advances AI-Powered Personalized Digital Healthcare
by Debanjana Dey
HIMS accelerates AI-powered care with new tech leadership, personalized treatments and a major $870 million investment push.
HIMS Stock Declines Despite Launch of New Specialty in Women's Health
by Zacks Equity Research
Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.
HQY Expands Access With GLP-1 Telehealth & Direct HSA Platforms
by Zacks Equity Research
HealthEquity rolls out GLP-1 telehealth and direct HSA enrollment platforms, targeting affordability and growth amid rising healthcare costs and regulatory expansion.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
OMCL or HIMS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) reached $59.15 at the closing of the latest trading day, reflecting a -5.75% change compared to its last close.
Hims & Hers Elevates Technology-Driven Healthcare Accessibility
by Debanjana Dey
HIMS boosts AI-led care with new technology chief, hormone therapies and a global push via its ZAVA acquisition.
Hims & Hers Gains 3.8% in 3 Months: Time to Hold the Stock or Sell?
by Debanjana Dey
HIMS expands into men's health and hormones, but rising costs and regulatory hurdles threaten its momentum.
Hims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $53.96, signifying a -7.36% move from its prior day's close.
Hims & Hers Expands Personalized Care Access Via Telehealth Platform
by Debanjana Dey
HIMS expands its AI-powered telehealth platform, boosting personalized care and eyeing international growth in 2026.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers Expands Health Access Through Subscription Revenue Model
by Zacks Equity Research
HIMS boosts predictable revenue and customer loyalty with a flexible, subscription-based model across key health categories.
OMCL or HIMS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
by Zacks Equity Research
The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $59.12, representing a +1.23% change from its previous close.
HIMS vs. DOCS: Which Digital Health Platform Is a Better Investment?
by Debanjana Dey
Hims & Hers and Doximity are transforming digital health, but which leads in earnings growth and platform expansion? Let's see.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $56, signifying a -2.95% move from its prior day's close.
Hims & Hers Expands Care Ecosystem via Global and Digital Innovation
by Zacks Equity Research
HIMS is scaling globally with AI-powered care, new treatments and an $870 million boost to expand its digital ecosystem.